docetaxel, cisplatin, and capecitabine — Competitive Intelligence Brief

docetaxel, cisplatin, and capecitabine (docetaxel, cisplatin, and capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane, Platinum-based chemotherapeutic, Antimetabolite. Area: Oncology.

phase 3 Taxane, Platinum-based chemotherapeutic, Antimetabolite Microtubules, DNA Oncology Small molecule

Target snapshot

docetaxel, cisplatin, and capecitabine (docetaxel, cisplatin, and capecitabine) — Sun Yat-sen University. Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death. Capecitabine is a prodrug of 5-fluorouracil, which inhibits thymidylate synthase, disrupting DNA synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
docetaxel, cisplatin, and capecitabine TARGET	docetaxel, cisplatin, and capecitabine	Sun Yat-sen University	phase 3	Taxane, Platinum-based chemotherapeutic, Antimetabolite	Microtubules, DNA
docetaxel, nedaplatin, and capecitabine	docetaxel, nedaplatin, and capecitabine	Sun Yat-sen University	phase 3	Taxane, Platinum-based DNA crosslinker, Thymidylate synthase inhibitor	Microtubules, DNA, Thymidylate synthase
Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent	PD-1, VEGF, microtubules, DNA
cyclophosphamide, vincristine, prednisone, dacarbazine	cyclophosphamide, vincristine, prednisone, dacarbazine	University of Giessen	phase 3	Alkylating agent, Vinca alkaloid, Corticosteroid	Microtubules, DNA
Vincristine + Carboplatin + Etoposide	Vincristine + Carboplatin + Etoposide	St. Jude Children's Research Hospital	phase 3	Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor	Microtubules, DNA
epidoxorubicine, docetaxel, cyclophosphamide	epidoxorubicine, docetaxel, cyclophosphamide	Sanofi	phase 3	anthracycline antibiotic, taxane, alkylating agent	topoisomerase II, microtubules, DNA
Gemcitabine, Vinorelbine, Eribulin, or Utidelone	Gemcitabine, Vinorelbine, Eribulin, or Utidelone	Sun Yat-sen University	phase 3	Chemotherapy combination (nucleoside analog, vinca alkaloid, microtubule inhibitor, microtubule stabilizer)	Multiple: ribonucleotide reductase, microtubules, DNA synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane, Platinum-based chemotherapeutic, Antimetabolite class)

1. Sun Yat-sen University · 1 drug in this class